Search

Displaying results 2961 - 2970 of 7503 in total
  1. Drug

    Nialamide

    go.drugbank.com/drugs/DB04820
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.

    Categories: Monoamine Oxidase Inhibitors, Non-Selective, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: N-Isonicotinoyl-N'(beta-N-benzylcarboxamidoethyl)hydrazine, N-(2-(Benzylcarbamyl)ethylamino)isonicotinamide
  2. Drug

    Dyclonine

    go.drugbank.com/drugs/DB00645
    ApprovedInvestigational

    Dyclonine is an oral anaesthetic found in Sucrets, an over the counter throat lozenge. It may also be found in some Cepacol sore throat spray products.

    Synonyms: 4-n-butoxy-β-(1-piperidyl)propiophenone
  3. Drug

    Diethylstilbestrol

    go.drugbank.com/drugs/DB00255
    ApprovedWithdrawn

    According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen.

    Categories: Estrogens, Non-Steroidal
  4. Drug

    MMDA

    go.drugbank.com/drugs/DB01442
    ExperimentalIllicit

    MMDA bears resemblance to the psychopharmacologically active essential oils elemicin and myristicin found in nutmeg.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Pertuzumab

    go.drugbank.com/drugs/DB06366
    ApprovedInvestigational

    It was first approved by the FDA in 2012 for use with [docetaxel] and another HER2-targeted monoclonal antibody, [trastuzumab], in the treatment of metastatic HER2-positive breast cancer. … Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.

  6. Drug

    Fosamprenavir

    go.drugbank.com/drugs/DB01319
    ApprovedInvestigational

    Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.

  7. Drug

    Zanidatamab

    go.drugbank.com/drugs/DB15471
    ApprovedInvestigational

    Zanidatamab is a bispecific antibody that binds two non-overlapping sites of HER2 (ERBB2).

    Synonyms: SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY, BIPARATOPIC (TARGETING TWO DIFFERENT NON-OVERLAPP
  8. Drug

    Mesterolone

    go.drugbank.com/drugs/DB13587
    Investigational

    It is inactivated by 3α-hydroxysteroid dehydrogenase in skeleta muscules so it is considered a weak androgen. It is not a substrate for aromatase so it is not converted into estrogen. … Mesterolone demonstrated to have minimal effect on sperm counts and levels of FSH or LH [A27177, A27178].

  9. Drug

    Aceclidine

    go.drugbank.com/drugs/DB13262
    Approved

    , and lens anterior displacement, leading to reduced risk of retina or vitreous tractions. … [A274283] As compared to less selective miotics, like [pilocarpine], aceclidine's relative stimulation of the ciliary muscle is significantly less and, as such, induces far less myopic shift, lens thickening

  10. Drug

    MDX-214

    go.drugbank.com/drugs/DB06110
    Experimental

    MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector